Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Seasonal Flu Vaccine on H5N1 Immune Response
NCT03701061Phase 4Completed
- Sponsor
- Emory University
- Start
- Oct 2018
- Primary completion
- Feb 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Influsplit in influenza (2 arms), sponsored by Emory University. Primary endpoint: Number of Participants With a Four-fold Increase in Stem-specific Antibody Titers (H5, Hemagglutinin Antibody) Against H5N1 at Day 29. Started Oct 2018; status: completed.
02
Drugs
Influsplit
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03701061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03701061.